Cargando…

Completion of 6-mo isoniazid preventive treatment among eligible under six children: A cross-sectional study, Lagos, Nigeria

BACKGROUND: Nigeria is one of the thirty high burden countries with significant contribution to the global childhood tuberculosis epidemic. Tuberculosis annual risk for children could be as high as 4% particularly in high tuberculosis (TB) prevalent communities. Isoniazid (INH) Preventive Therapy ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Adepoju, Victor Abiola, Adelekan, Ademola, Agbaje, Aderonke, Quaitey, Femi, Ademola-Kay, Tobi, Udoekpo, Ann Uduak, Sokoya, Olusola Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9846979/
https://www.ncbi.nlm.nih.gov/pubmed/36687175
http://dx.doi.org/10.12998/wjcc.v11.i1.104
_version_ 1784871325925376000
author Adepoju, Victor Abiola
Adelekan, Ademola
Agbaje, Aderonke
Quaitey, Femi
Ademola-Kay, Tobi
Udoekpo, Ann Uduak
Sokoya, Olusola Daniel
author_facet Adepoju, Victor Abiola
Adelekan, Ademola
Agbaje, Aderonke
Quaitey, Femi
Ademola-Kay, Tobi
Udoekpo, Ann Uduak
Sokoya, Olusola Daniel
author_sort Adepoju, Victor Abiola
collection PubMed
description BACKGROUND: Nigeria is one of the thirty high burden countries with significant contribution to the global childhood tuberculosis epidemic. Tuberculosis annual risk for children could be as high as 4% particularly in high tuberculosis (TB) prevalent communities. Isoniazid (INH) Preventive Therapy has been shown to prevent TB incidence but data on its implementation among children are scarce. AIM: To determine the completion of INH among under six children that were exposed to adults with smear positive pulmonary TB in Lagos, Nigeria. METHODS: This was a hospital-based retrospective cross-sectional review of 265 medical records of eligible children < 6 years old enrolled for INH across 32 private hospitals in Lagos, Nigeria. The study took place between July and September 2020. Data was collected on independent variables (age, gender, type of facility, TB screening, dose and weight) and outcome variables (INH outcome and proportion lost to follow up across months 1-6 of INH treatment). RESULTS: About 53.8% of the participants were female, 95.4% were screened for TB and none was diagnosed of having TB. The participants’ age ranged from 1 to 72 mo with a mean of 36.01 ± 19.67 mo, and 40.2% were between the ages of 1-24 mo. Only 155 (59.2%) of the 262 participants initiated on INH completed the six-month treatment. Cumulatively, 107 (41.0%) children were lost to follow-up at the end of the sixth month. Of the cumulative 107 loss to follow-up while on INH, largest drop-offs were reported at the end of month 2, 52 (49%) followed by 20 (19%), 17 (16%), 11 (10.2%) and 7 (6.5%) at months 3, 4, 5 and 6 respectively. The analysis showed that there was no significant association between age, gender, type of facility and completion of INH treatment (P > 0.005). CONCLUSION: This study demonstrated suboptimal INH completion rate among children with only 6 out of 10 children initiated on INH who completed a 6-mo treatment in Lagos, Nigeria. The huge drop-offs in the first 2 mo of INH calls for innovative strategies such as the use of 60-d INH calendar that would facilitate reminder and early engagement of children on INH and their caregivers in care and across the entire period of treatment.
format Online
Article
Text
id pubmed-9846979
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-98469792023-01-19 Completion of 6-mo isoniazid preventive treatment among eligible under six children: A cross-sectional study, Lagos, Nigeria Adepoju, Victor Abiola Adelekan, Ademola Agbaje, Aderonke Quaitey, Femi Ademola-Kay, Tobi Udoekpo, Ann Uduak Sokoya, Olusola Daniel World J Clin Cases Retrospective Cohort Study BACKGROUND: Nigeria is one of the thirty high burden countries with significant contribution to the global childhood tuberculosis epidemic. Tuberculosis annual risk for children could be as high as 4% particularly in high tuberculosis (TB) prevalent communities. Isoniazid (INH) Preventive Therapy has been shown to prevent TB incidence but data on its implementation among children are scarce. AIM: To determine the completion of INH among under six children that were exposed to adults with smear positive pulmonary TB in Lagos, Nigeria. METHODS: This was a hospital-based retrospective cross-sectional review of 265 medical records of eligible children < 6 years old enrolled for INH across 32 private hospitals in Lagos, Nigeria. The study took place between July and September 2020. Data was collected on independent variables (age, gender, type of facility, TB screening, dose and weight) and outcome variables (INH outcome and proportion lost to follow up across months 1-6 of INH treatment). RESULTS: About 53.8% of the participants were female, 95.4% were screened for TB and none was diagnosed of having TB. The participants’ age ranged from 1 to 72 mo with a mean of 36.01 ± 19.67 mo, and 40.2% were between the ages of 1-24 mo. Only 155 (59.2%) of the 262 participants initiated on INH completed the six-month treatment. Cumulatively, 107 (41.0%) children were lost to follow-up at the end of the sixth month. Of the cumulative 107 loss to follow-up while on INH, largest drop-offs were reported at the end of month 2, 52 (49%) followed by 20 (19%), 17 (16%), 11 (10.2%) and 7 (6.5%) at months 3, 4, 5 and 6 respectively. The analysis showed that there was no significant association between age, gender, type of facility and completion of INH treatment (P > 0.005). CONCLUSION: This study demonstrated suboptimal INH completion rate among children with only 6 out of 10 children initiated on INH who completed a 6-mo treatment in Lagos, Nigeria. The huge drop-offs in the first 2 mo of INH calls for innovative strategies such as the use of 60-d INH calendar that would facilitate reminder and early engagement of children on INH and their caregivers in care and across the entire period of treatment. Baishideng Publishing Group Inc 2023-01-06 2023-01-06 /pmc/articles/PMC9846979/ /pubmed/36687175 http://dx.doi.org/10.12998/wjcc.v11.i1.104 Text en ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Retrospective Cohort Study
Adepoju, Victor Abiola
Adelekan, Ademola
Agbaje, Aderonke
Quaitey, Femi
Ademola-Kay, Tobi
Udoekpo, Ann Uduak
Sokoya, Olusola Daniel
Completion of 6-mo isoniazid preventive treatment among eligible under six children: A cross-sectional study, Lagos, Nigeria
title Completion of 6-mo isoniazid preventive treatment among eligible under six children: A cross-sectional study, Lagos, Nigeria
title_full Completion of 6-mo isoniazid preventive treatment among eligible under six children: A cross-sectional study, Lagos, Nigeria
title_fullStr Completion of 6-mo isoniazid preventive treatment among eligible under six children: A cross-sectional study, Lagos, Nigeria
title_full_unstemmed Completion of 6-mo isoniazid preventive treatment among eligible under six children: A cross-sectional study, Lagos, Nigeria
title_short Completion of 6-mo isoniazid preventive treatment among eligible under six children: A cross-sectional study, Lagos, Nigeria
title_sort completion of 6-mo isoniazid preventive treatment among eligible under six children: a cross-sectional study, lagos, nigeria
topic Retrospective Cohort Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9846979/
https://www.ncbi.nlm.nih.gov/pubmed/36687175
http://dx.doi.org/10.12998/wjcc.v11.i1.104
work_keys_str_mv AT adepojuvictorabiola completionof6moisoniazidpreventivetreatmentamongeligibleundersixchildrenacrosssectionalstudylagosnigeria
AT adelekanademola completionof6moisoniazidpreventivetreatmentamongeligibleundersixchildrenacrosssectionalstudylagosnigeria
AT agbajeaderonke completionof6moisoniazidpreventivetreatmentamongeligibleundersixchildrenacrosssectionalstudylagosnigeria
AT quaiteyfemi completionof6moisoniazidpreventivetreatmentamongeligibleundersixchildrenacrosssectionalstudylagosnigeria
AT ademolakaytobi completionof6moisoniazidpreventivetreatmentamongeligibleundersixchildrenacrosssectionalstudylagosnigeria
AT udoekpoannuduak completionof6moisoniazidpreventivetreatmentamongeligibleundersixchildrenacrosssectionalstudylagosnigeria
AT sokoyaolusoladaniel completionof6moisoniazidpreventivetreatmentamongeligibleundersixchildrenacrosssectionalstudylagosnigeria